SUMMARY
Amylou C. Dueck, Ph.D., designs and analyzes cancer clinical trials, primarily in breast cancer and hematologic malignancies. Dr. Dueck also analyzes associated biomarker and questionnaire data within cancer clinical trials.
Dr. Dueck is an expert in the design, statistical analysis and interpretation of patient-reported outcomes and symptom end points in cancer clinical trials. Her primary research interests are development of tools for patients to self-report symptoms in cancer clinical trials, statistical analysis and visualization approaches for patient-reported outcomes, and measurement of physical function using patient-reported outcomes and other modalities.
Dr. Dueck was a key member of the Development Group for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). She also was the principal investigator of the primary validation study of PRO-CTCAE, which is a library of 124 items measuring 78 symptomatic adverse events for patient self-reporting in cancer clinical trials.
In collaboration with Ruben A. Mesa, M.D., Dr. Dueck developed the Myeloproliferative Neoplasm Symptom Assessment Form. This form measures symptom burden and quality of life in patients with myeloproliferative neoplasm symptoms.
Focus areas
- Design and analysis of cancer clinical trials, including pragmatic trials and trials of cancer care delivery interventions.
- Development of tools for patients to self-report symptoms in cancer clinical trials.
- Statistical analysis and visualization approaches for patient-reported outcomes.
- Measurement of physical function using patient-reported outcomes and other modalities, including wearable devices.
Significance to patient care
Dr. Dueck's collaborations and research test the safety and effectiveness of cancer treatments while including the patient voice in the testing process. She is increasing the number of safe treatment options and enhancing the information available to make treatment decisions for patients who have cancer.
Professional highlights
- Vice chair, Quantitative Health Sciences, Mayo Clinic, 2019-present.
- Co-chair, Health Outcomes Committee, Alliance for Clinical Trials in Oncology, 2017-present.
- Chair, Cancer Moonshot Treatment Tolerability Consortium, National Cancer Institute, 2018-2024.
- Inductee, College Leaders, College of Liberal Arts and Sciences, Arizona State University, 2023.